PET/CT quantitation of the effect of patient-related factors on cardiac 18F-FDG uptake

J Nucl Med. 2007 Feb;48(2):234-9.

Abstract

The effect of multiple patient-related factors on the degree of cardiac 18F-FDG uptake was assessed.

Methods: Five hundred four consecutive patients undergoing routine 18F-FDG PET/CT studies completed a clinical questionnaire. 18F-FDG uptake was measured as the mean standardized uptake value within the heart delineated on the CT component of the study. Univariate and multivariate analyses assessed the influence of 51 clinical factors on cardiac 18F-FDG uptake.

Results: On both multivariate and univariate analyses, cardiac 18F-FDG uptake was significantly lower in diabetics and in patients receiving bezafibrate or levothyroxine. Cardiac 18F-FDG uptake was significantly higher in men, patients younger than 30 y old, fasting duration of <5 h, patients with heart failure, and those receiving benzodiazepines.

Conclusion: Cardiac 18F-FDG uptake was lower in patients receiving bezafibrate and levothyroxine and higher in patients receiving benzodiazepines. If further confirmed by prospectively designed studies, manipulation of these drugs may represent tools for optimized PET/CT imaging.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Aging / metabolism
  • Benzodiazepines / adverse effects
  • Bezafibrate / adverse effects
  • Diabetes Mellitus / metabolism
  • Drug Interactions
  • Female
  • Fluorodeoxyglucose F18 / pharmacokinetics*
  • Heart / diagnostic imaging*
  • Heart Diseases / diagnostic imaging*
  • Heart Diseases / metabolism*
  • Humans
  • Hypolipidemic Agents / adverse effects
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Myocardium / metabolism*
  • Positron-Emission Tomography
  • Radiopharmaceuticals / pharmacokinetics*
  • Thyroxine / adverse effects
  • Tomography, X-Ray Computed
  • Whole-Body Counting

Substances

  • Hypolipidemic Agents
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18
  • Benzodiazepines
  • Thyroxine
  • Bezafibrate